Lipid lowering, antiinflammatory, and vasoprotective effects of fenofibrate in patients with type 2 diabetes mellitus

Kardiologiya

Volumn 50, Issue 5, 2010, Pages 36-41

  Tkacheva, O N ^a   Sharashkina, N V ^a   Novikova, I M ^a   Torshkhoeva, Kh M ^a  

^a RESEARCH CENTER OF OBSTETRICS   (Russian Federation)

Author keywords

Diabetes mellitus; Dyslipidemias; Fenofibrate

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; FENOFIBRATE; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; STATISTICAL ANALYSIS; TIME; VASODILATATION;

ADULT; AGED; C-REACTIVE PROTEIN; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PATIENT SELECTION; TIME FACTORS; URIC ACID; VASODILATION;

EID: 79952113472     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kannel W.B., McGee D L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingam Study. Diabetes Care 1979; 2: 120-126. (Pubitemid 9238733)
2. Chapman M.J., Brucken E. The aterogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Atherosclerosis 1996; 124: 921-928.
3. Tan C.E., Chew L.S., Chio L.F. et al. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control Diabetes Res Clin Pract 2001; 51: 107-114. (Pubitemid 32140862)
4. Caslake M.J., Packard C.J., Gaw N. et al. Fenofibrate and LDL metabolic heterogeneity in hypercholsterolenua. Arterioscler Thromb 1993; 13: 702-713.
5. National Diabetes Education Program. Control the ABCs of Diabetes. 2002.
6. Batgent C, Keech A., Kearney P.M. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
7. Miller M., Cannon C.P., Murphy S.A. et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 2008; 51: 724-730. (Pubitemid 351221217)
8. Bardot O., Aldridge T.C., Latruffe N., Green S. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun 1993; 192: 37-45. (Pubitemid 23205265)
9. Brown W. V., Dujovne C, Farquhar J.W. et al. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 1986; 6: 670-678. (Pubitemid 17190167)
10. Keech A., Simes R.J., Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
11. Celermajer D.S., Sorensen K.E., Bull C. et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interactions. J Am Coll Cardiol 1994; 24: 1468-1474. (Pubitemid 24344241)
12. Frlck M.H., Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. NEIM 1987; 20: 1237-1245. (Pubitemid 17147964)
13. Rubins H.B., Robins S.J., Collins D. et al. for the Veterans Affaires High - Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the Secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418. (Pubitemid 29362514)
14. Goldbourt U., Brunner D., Behar S., Reicher S.H. Baseline characteristics of patients, participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 1998; 19: 42-47.
15. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.
16. Vu-Dac N., Schoonjans K., Kosykh V., Dallongevllle J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995; 96: 741-750.
17. Warren H, Capell D., Christopher A. Short-Term Triglyceride Lowering With Fenofibrate Improves Vasodilator Function in Subjects With Hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003; 23: 307.
18. Hiukka A., Westerbacka J., Leinonen E.S. et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52: 2190-2197.
19. Hamilton S.J., Chew G. T., Davis T. et al. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients Clin Science 2010; 118: 607-615.
20. Zhu S., Su G., Meng Q.H. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem 2006; 52: 2036-2042. (Pubitemid 44658204)
21. Schoonjans K, Peinado-Onsurba J., Lefebwe A.-M. et al. PPARa and PPARg activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein Upase gene. EMBO J 1996; 15: 5336-5348. (Pubitemid 26336216)
22. Muhtestein J. B., May H.T., Jensen J. R. et al. The reduction of inflammatory biomarkers by statin, fibrate and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combination therapy Regimen) study. J Am Coll Cardiol 2006, 48: 396-401.
23. Rosenson R. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity 2009; 17: 504-509.
24. Okoplen B., Krysiak R., Herman Z.S. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91: 1770-1778.
25. de la Sema G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther 1999; 66: 2: 166-172. (Pubitemid 29398852)
26. Cullettn B.F., Larson M.G., Kannel W.B., Levy D. Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7-13. (Pubitemid 29310011)
27. Schram M.T., Schalkwijk CG, Bootsma A.H. et al. EURODIAB Prospective Complications Study Group: Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 2005; 46: 232-237. (Pubitemid 40946520)
28. Levistanou D., Melidonls A., Adamopoulou E. et al. Impact of the metabolic syndrome and its com-ponents combinations on arterial stiffness in Type 2 diabetic men Int Angiol 2009; 28: 490-495.